Repertoire and Frequency of Immune Cells Reactive to Epstein-Barr Virus-derived Autologous Lymphoblastoid Cell Lines

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2007 Oct 19

PMID 17942757

Citations 13

Authors

Sumita Bhaduri-McIntosh

Marisa J Rotenberg

Benjamin Gardner

Marie Robert

George Miller

Affiliations

Soon will be listed here.

Abstract

Answers to questions about frequency and repertoire of immune cells, relative contributions made by different types of immune cells toward the total Epstein-Barr virus (EBV)-directed response and the variation of such responses in healthy persons have been elusive because of disparities in assays, antigen presenting cells, and antigenic sources used in previous experiments. In this study, we addressed these questions using an assay that allowed direct comparison of responses generated by different types of cells of the immune system. This short-term (20-hour) ex vivo assay measured interferon-gamma production by blood cells in response to autologous EBV-transformed lymphoblastoid cell lines (LCLs). Our experiments defined the variation in responses among persons and clearly distinguished 10 healthy EBV-immune from 10 healthy EBV-naive persons. In EBV-immune persons, 33% of responding cells were CD4(+), 43.3% were CD8(+), and 12.9% were gamma-delta T cells. LCL-reactive CD8(+) T cells were only 1.7-fold more frequent than similarly reactive CD4(+)T cells. Responses by gamma-delta T cells were 6-fold higher in seropositive than in seronegative persons. Our findings emphasize the importance of CD4(+) and gamma-delta T-cell responses and have implications for immunotherapy and for identifying defects in T-cell populations that might predispose to development of EBV-associated lymphomas.

Citing Articles

Extensive proteome and functional genomic profiling of variability between genetically identical human B-lymphoblastoid cells.

Laczik M, Erdos E, Ozgyin L, Hevessy Z, Csosz E, Kallo G Sci Data. 2022; 9(1):763.

PMID: 36496436 PMC: 9741606. DOI: 10.1038/s41597-022-01871-9.

Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires.

Grunert C, Willimsky G, Peuker C, Rhein S, Hansmann L, Blankenstein T Cancers (Basel). 2022; 14(7).

PMID: 35406613 PMC: 8998067. DOI: 10.3390/cancers14071842.

Extensive epigenetic and transcriptomic variability between genetically identical human B-lymphoblastoid cells with implications in pharmacogenomics research.

Ozgyin L, Horvath A, Hevessy Z, Balint B Sci Rep. 2019; 9(1):4889.

PMID: 30894562 PMC: 6426863. DOI: 10.1038/s41598-019-40897-9.

Efficient Culture of Human Naive and Memory B Cells for Use as APCs.

Su K, Watanabe A, Yeh C, Kelsoe G, Kuraoka M J Immunol. 2016; 197(10):4163-4176.

PMID: 27815447 PMC: 5111638. DOI: 10.4049/jimmunol.1502193.

Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire.

Sims J, Grinshpun B, Feng Y, Ung T, Neira J, Samanamud J Proc Natl Acad Sci U S A. 2016; 113(25):E3529-37.

PMID: 27261081 PMC: 4922177. DOI: 10.1073/pnas.1601012113.

References

Khanna R, Burrows S . Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol. 2000; 54:19-48. DOI: 10.1146/annurev.micro.54.1.19. View

Rickinson A, Moss D, Wallace L, Rowe M, Misko I, Epstein M . Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res. 1981; 41(11 Pt 1):4216-21. View

Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A . Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999; 401(6754):708-12. DOI: 10.1038/44385. View

Precopio M, Sullivan J, Willard C, Somasundaran M, Luzuriaga K . Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J Immunol. 2003; 170(5):2590-8. DOI: 10.4049/jimmunol.170.5.2590. View

Hislop A, Annels N, Gudgeon N, Leese A, Rickinson A . Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med. 2002; 195(7):893-905. PMC: 2193726. DOI: 10.1084/jem.20011692. View

Hochberg D, Middeldorp J, Catalina M, Sullivan J, Luzuriaga K, Thorley-Lawson D . Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A. 2003; 101(1):239-44. PMC: 314169. DOI: 10.1073/pnas.2237267100. View

Joseph A, Babcock G, Thorley-Lawson D . Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol. 2000; 74(21):9964-71. PMC: 102034. DOI: 10.1128/jvi.74.21.9964-9971.2000. View

Hamilton-Dutoit S, Rea D, Raphael M, Sandvej K, Delecluse H, Gisselbrecht C . Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol. 1993; 143(4):1072-85. PMC: 1887058. View

Munz C, Bickham K, Subklewe M, Tsang M, Chahroudi A, Kurilla M . Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med. 2000; 191(10):1649-60. PMC: 2193162. DOI: 10.1084/jem.191.10.1649. View

10.

Woodberry T, Suscovich T, Henry L, Davis J, Frahm N, Walker B . Differential targeting and shifts in the immunodominance of Epstein-Barr virus--specific CD8 and CD4 T cell responses during acute and persistent infection. J Infect Dis. 2005; 192(9):1513-24. DOI: 10.1086/491741. View

11.

Babcock G, Decker L, Volk M, Thorley-Lawson D . EBV persistence in memory B cells in vivo. Immunity. 1998; 9(3):395-404. DOI: 10.1016/s1074-7613(00)80622-6. View

12.

Miller W, EDWARDS R, Walling D, Raab-Traub N . Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol. 1994; 75 ( Pt 10):2729-40. DOI: 10.1099/0022-1317-75-10-2729. View

13.

Gudgeon N, Taylor G, Long H, Haigh T, Rickinson A . Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. J Virol. 2005; 79(9):5477-88. PMC: 1082738. DOI: 10.1128/JVI.79.9.5477-5488.2005. View

14.

Nikiforow S, Bottomly K, Miller G . CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol. 2001; 75(8):3740-52. PMC: 114865. DOI: 10.1128/JVI.75.8.3740-3752.2001. View

15.

Long H, Haigh T, Gudgeon N, Leen A, Tsang C, Brooks J . CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol. 2005; 79(8):4896-907. PMC: 1069546. DOI: 10.1128/JVI.79.8.4896-4907.2005. View

16.

Khanna R, Burrows S, Thomson S, Kurilla M, Moss D . Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology. 1995; 214(2):633-7. DOI: 10.1006/viro.1995.0076. View

17.

OLeary J, Goodarzi M, Drayton D, von Andrian U . T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol. 2006; 7(5):507-16. DOI: 10.1038/ni1332. View

18.

Khanna R, Burrows S, Thomson S, Moss D, Cresswell P, Poulsen L . Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs. J Immunol. 1997; 158(8):3619-25. View

19.

Leen A, Meij P, Redchenko I, Middeldorp J, Bloemena E, Rickinson A . Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001; 75(18):8649-59. PMC: 115110. DOI: 10.1128/jvi.75.18.8649-8659.2001. View

20.

Tan L, Gudgeon N, Annels N, Hansasuta P, OCallaghan C, Rowland-Jones S . A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 1999; 162(3):1827-35. View